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Abstract 
Central nervous system demyelinating processes such as multiple sclerosis and acute 
disseminated encephalomyelitis constitute a group of diseases not completely 
understood in their physiopathology. Environmental and toxic insults are thought to 
play a role in priming autoimmunity. The aim of the present report is to describe a case 
of acute demyelinating disease with fatal outcome occurring 15 days after oral exposure 
to herbal extracts. 
 
Introduction 
The approach usually taken by the general population to phytomedicine is that such a 
therapy is natural and therefore safe, but several studies have demonstrated that this 
statement is not true. The relationship between the use of herbal compounds, alone or in 
combination with traditional drugs, and the occurrence of side effects have been 
described. Phytomedicine has been shown to be related to toxic leukoencephalopathy [1] 
among other disorders. Moreover, two cases of acute disseminated encephalomyelitis 
(ADEM) after exposure to intravenous herbal extracts have been reported [2]. Case Rep Neurol 2011;3:141–146 
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Herein we report the case of a patient who suffered an acute demyelinating disorder 
with severe and persistent neurologic impairment (finally leading to a fatal outcome) 
temporally related to the use of an oral therapy that contained herbal extracts. 
Patient and Methods 
A 63-year-old woman was admitted to our hospital with a 7-day history of asthenia, postural 
instability and falls. Her past medical history included hypertension, Hashimoto’s thyroiditis (with 
detectable anti-thyroglobulin and anti-peroxidase autoantibodies), benign leukopenia and cervical 
arthrosis. She worked as a yoga teacher before admission. The patient had no history of vaccination or 
viral infection in the last year. Fifteen days before the onset of the symptoms she had started a 
homeopathic treatment for cervical pain. The formulation of tablets (labelled as ‘immunostimulant’) 
consisted of Echinacea purpurea 45 mg, Uncaria tomentosa 37.5 mg, and Tabebuia avellanedae and 
Plantago maritima 30 mg. 
On admission, vital signs were normal. The patient was awake, alert and oriented. Neurological 
examination revealed the presence of left-eye horizontal nystagmus, mild dysarthria, and mild right arm 
weakness together with both axial and appendicular ataxia. The rest of the physical examination was 
unremarkable. Blood test showed mild leukopenia (without neutropenia) as the only altered parameter. 
Cranial T2-weighted and FLAIR sequences on magnetic resonance image (MRI) showed 
pseudonodular, subcortical and periventricular bilateral white matter lesions with heterogeneous 
gadolinium enhancement. High signal on an apparent diffusion coefficient map was compatible with 
vasogenic edema (fig. 1a). Cerebrospinal fluid (CSF) analysis showed a mild increase in protein 
concentration (60 mg/dl, ≤45 mg/dl) without pleocytosis. CSF cultures were negative. CSF and serum 
oligoclonal bands, CSF VDRL and herpes simplex virus PCR were negative. Antinuclear antibodies were 
undetectable. 
On hospital day 6, central right facial nerve paralysis was observed. On the following day, the patient 
became lethargic and bilateral clonus and Babinski signs were present. The patient was admitted to the 
intensive care unit (ICU) because of impaired consciousness, and intravenous methylprednisolone was 
started, due to the presumptive diagnosis of a central nervous system (CNS) demyelinating process. The 
patient developed generalized tonic clonic seizures requiring anti-convulsant therapy, sedation and 
mechanical ventilation. Repeat MRI showed progression of the previously described lesions and 
involvement of the cerebellum (fig. 1b). 
Computer tomography (CT)-guided stereotactic biopsy was performed, and pathology 
demonstrated features compatible with acute demyelination (fig. 1c). Brain biopsy PCR was negative for 
Mycobacterium tuberculosis, JC and BK viruses. The biopsy specimen was reviewed for the presence of 
an immune cell infiltrate using immunohistochemical markers for T cells (CD3) and B cells (CD20). 
The tissue harbored a considerable immune cell infiltrate including significant numbers of T cells that 
were distributed throughout the tissue (fig. 2a) and present in more compact clusters (fig. 2b). B cells 
were fewer in number than T cells and more sparsely distributed (fig. 2c) although they were also 
present in more compact clusters (fig. 2d). 
Total treatment scheme included 3 g methylprednisolone i.v., oral steroids, five plasma exchange 
sessions and 120 g immunoglobulin i.v., without major improvement of the symptoms that required 
treatment in our ICU. After 2 months of respiratory assistance, the patient was released from 
mechanical ventilation. However, no significant neurologic recovery was achieved.  
The patient was discharged to a rehabilitation facility; she was quadriparetic, required help in daily 
activities, and was fed through a percutaneous endoscopic gastrostomy tube. Her level of consciousness 
was impaired and she was barely able to connect with her family members. A follow-up brain MRI at 8 
months showed atrophy and scarring; no new lesions had occurred (fig. 1d). Two years after the initial 
demyelinating event, the patient died of septic shock. Case Rep Neurol 2011;3:141–146 
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Discussion 
To our knowledge, this is the second report that links the use of herbal extracts and 
demyelinating disorders of the CNS, and the first with oral phytotherapy. 
Up to three quarters of the monophasic demyelinating disease of the CNS may be 
regarded as post-infectious or post-immunization processes [3]. Typically, the latency 
until the onset of neurological symptoms is 7–14 days after the causative insult. In our 
case, the patient had started the herbal extract (putative triggering event) 2 weeks earlier. 
Although our case showed many features compatible with ADEM (evidence of 
demyelination, monophasic nature, absence of oligoclonal bands in CSF and grey matter 
involvement) [4], the unremitting, progressive and persistent severe sequelae made us 
view it as an acute, otherwise unclassified immune-mediated demyelination event [5, 6]. 
The finding of foamy histiocytes, together with an intense T cell (and to a lesser extent B 
cell) infiltrate within the lesions, points to an autoreactive immune mechanism towards 
myelin as the main pathogenic mechanism.  
Multiple sclerosis and related demyelinating disorders are an expression of 
autoimmunity within the CNS. Many immunological players have been proven to take 
part in its pathophysiology, including Th1, Th17, regulatory T cells, antigen presenting 
cells and B cells [7], among many others. Susceptibility genes [8] and serum autoantibody 
patterns [9] have been described. However, the exact factors that trigger autoimmunity 
have not yet been identified; ambient insults are thought to play a major role. 
Experimental data has shown that Echinacea may have immunostimulant properties [10], 
such as an increase in cytokine production by human macrophages [11], but these results 
have not convincingly been proven in clinical studies. On the other hand, numerous 
adverse immune reactions, including anaphylactic responses, urticaria, Löfgren’s 
syndrome, vasculitis, and erythema multiforme, have been described. Development of an 
autoimmune reaction following use of so-called ‘immunostimulatory’ herbal supplements 
has also been reported [12].  
The long tradition and presumed natural origin of herbal medicines do not translate to 
a guarantee for treatment safety. Currently, more than 1,000 plants are sold worldwide, 
although clinical trials have been published only for 156 plants supporting specific 
pharmacological activities and therapeutic applications [13]. Furthermore, the largest 
study on this topic shows that severe adverse reactions (hospitalization, life-threatening 
clinical events and death) account for over one third of the undesired effects [14]. 
It is difficult to argue that the immune-mediated demyelinating disease detailed here 
was entirely due to the patient’s use of herbal extracts. However, both previous reports 
and temporal concomitance led us to the conclusion that such an association may be in 
part true and should be taken into account in the evaluation of future patients. We, as well 
as others [15], believe in the urgent need of regulatory controls, scientific evaluation and 
active pharmacovigilance in phytomedicine in order to avoid undesired and often 
unpredictable side effects. 
Disclosure Statement 
No conflict of interest is reported. Case Rep Neurol 2011;3:141–146 
DOI: 10.1159/000329734 
Published online: 
June 25, 2011 
© 2011 S. Karger AG, Basel
ISSN 1662–680X 
www.karger.com/crn   
 
 
 
144
Funding/Support 
Dr. O’Connor is a Nancy David Foundation for Multiple Sclerosis Young Investigator. 
 
 
 
 
 
 
Fig. 1. a MRI showed pseudonodular, subcortical and periventricular bilateral white matter lesions 
with heterogeneous gadolinium enhancement. b Repeat MRI on hospital day 6, showing progression of 
the previously described lesions and involvement of the cerebellum. c Hematoxylin-eosin stain 
showing features compatible with acute demyelination. d Follow-up brain MRI at 8 months showed 
atrophy and scarring. 
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Fig. 2. Immunohistochemistry. a, b CD3 markers for T cells. c, d CD20 markers for B cells. See text 
for further details. 
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